Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $110.00. The company’s shares closed last Friday at $99.70.

The new marketing authorization was granted on December 27 to Merck (MRK) Sharp & Dohme Limited. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

DARMSTADT, Germany, Jan. 7, 2025 /PRNewswire/ -- Merck, a leading science and technology company, today launched a beta version of M-Trust, a secure cyber-physical trust platform, created to help ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey · Reuters Reuters Thu, Dec 19, 2024, 6:58 a.m. (Reuters) - Merck said on Thursday its ...

Dec 19 (Reuters) - Merck's (MRK.N), opens new tab experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in adults receiving another form ...

Dec 18 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's (3692.HK), opens new tab experimental oral drug to treat ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

In a day that already included discontinuations from Roche and Foghorn Therapeutics, Merck & Co. rounded out Monday by announcing the termination of two late-stage cancer assets. The New Jersey ...

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million ...

RAHWAY, N.J., December 18, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...